HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Floss By Any Other Name Would Sell In Same Category – BBB National Programs Appeals Panel

NARB Decision On Perrigo Appeal Acknowledges Separate Flossers Category Could Emerge

Executive Summary

NARB panel concluded #1 claims challenged by Oral-B floss products marketer P&G aren’t supported by acceptable evidence that the type of product the claim referenced – flossers  – “is recognized as a consumer-relevant category."

You may also be interested in...



Perrigo Picks At Industry Self-Regulation Group Measuring Flosser Market By Units, Not Sales

NAD says “equivalized” sales data Perrigo submitted to support claim didn’t provide an accurate measure of flosser product category; instead, “un-equivalized” data P&G submitted were accurate measure. Perrigo counters that the decision conflated separate product categories as well as dismissed appropriate data.

Ranir Oral Care Deal Could Brighten Perrigo's Turnaround Chances

Ranir has a portfolio of more than 300 oral care solutions including power toothbrushes and heads, whitening strips, manual toothbrushes, floss, dentures and travel kits that it provides to retailers and other distributors in more than 50 countries. Adding Ranir, says Perrigo CEO Murray Kessler, "illustrates a key component of our new strategy, accelerating growth by pursuing adjacent self-care categories."

Perrigo Steers Through Transportation Obstacles, Soaring Shipping Costs From COVID-19

Perrigo largely has resolved distribution problems, but shipping freight costs still are much higher than pre-pandemic and it must divest a wound-care brand before US regulators sign off on acquisition of HRA Pharma, says CEO Murray Kessler during J.P. Morgan conference.

Topics

Related Companies

UsernamePublicRestriction

Register

RS152104

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel